MedicaidCoverageMedium impact
New Jersey Medicaid: Billing guidance for sickle cell disease treatments
UnitedHealthcare·NJ · Hematology, Oncology, Pediatrics +1 more·State news
We identified it
Jun 13, 2026
Summary
New Jersey Medicaid now participates in the CMS Cell and Gene Therapy Access Model, providing reduced-cost access to cell and gene therapies for sickle cell disease patients. Providers must follow new billing guidance, prior authorization requirements, and claim submission procedures for these specialized treatments.
Action Required
Immediately: Review the New Jersey Medicaid billing guidance for Sickle Cell Disease gene therapies document to understand provider requirements, applicable drugs, prior authorization processes, and claim submission procedures. Billing teams should familiarize themselves with the CGT Access Model requirements and update workflows for sickle cell disease gene therapy treatments for New Jersey Medicaid patients.